ENTA - NASDAQ

Enanta Pharmaceuticals, Inc.

ENTA·NASDAQ

$12.03

-6.6%

HealthcareBiotechnology

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$279.30M

EPS-3.8400

P/E Ratio-3.12

Earnings Date08/10/2026

enta

EPS

Last Annual Value

-3.84

3-Year CAGR

13%

5-Year CAGR

-16%

10-Year CAGR

-7%

Adjust for Inflation

Enanta Pharmaceuticals, Inc. Competitors Analysis of EPS

ENTA · NASDAQ

Company	EPS	CAGR 3Y	CAGR 5Y	CAGR 10Y
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA	-3.84	N/A	N/A	N/A
Assembly Biosciences, Inc. NASDAQ:ASMB	-0.55	N/A	N/A	N/A
Immuneering Corporation NASDAQ:IMRX	-1.27	N/A	N/A	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	-0.44	N/A	N/A	N/A
Sagimet Biosciences Inc. NASDAQ:SGMT	-1.58	N/A	N/A	N/A
Entrada Therapeutics, Inc. NASDAQ:TRDA	-3.47	N/A	N/A	N/A
Ventyx Biosciences, Inc. NASDAQ:VTYX	-1.97	N/A	N/A	N/A
Zura Bio Limited NASDAQ:ZURA	-1.06	N/A	N/A	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	-0.59	N/A	N/A	N/A
Caribou Biosciences, Inc. NASDAQ:CRBU	-1.59	N/A	N/A	N/A
Atea Pharmaceuticals, Inc. NASDAQ:AVIR	-1.94	N/A	N/A	N/A

Enanta Pharmaceuticals, Inc. Fair Value Envelope

ENTA · NASDAQ

Our analysis suggests that ENTA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.03, this represents a potential HIDDEN relative to our calculated worth for Enanta Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $12.03

Related Guides

Blog Categories

Continue your ENTA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.